MACOM Enhances Fronthaul Solutions With New Low Power EML Driver
The latest addition to the product line, the MALD-39071 Linear Driver with Equalizer, complements MACOM's existing portfolio of dual-, four- and eight-channel devices. Designed to support linear pluggable optics (LPO) modules, the MALD-39071 integrates input equalization, broad dynamic range and optional automatic gain control. It features high bandwidth, supports a variety of data rates and is tailored for cost and power efficiency in a variety of form factors, including SFP112, QSFP112, 800G OSFP and 800G QSFP-DD.
'Our latest EML driver solution is specifically designed for next generation mobile fronthaul,' said Stephen G. Daly, President and Chief Executive Officer, MACOM. 'As a member of the Mobile Optical Pluggable Alliance (MOPA), MACOM is focused on introducing high performance, low power optical solutions for 5G and future network buildouts.'
MACOM will highlight the MALD-39071 at OFC2025 during a technical presentation, 'Leveraging LPO for MOPA Fronthaul – Blueprints Beyond 5G,' on Tuesday, April 1, 2025 from 11:00 a.m. to 12:00 p.m. in Theater III, Moscone Center, San Francisco, California. MACOM's MALD-39071 will also be showcased in Booth 2028 from April 1 to 3, 2025.
About MACOM
MACOM designs and manufactures high-performance semiconductor products for the Telecommunications, Industrial and Defense, and Data Center industries. MACOM services over 6,000 customers annually with a broad product portfolio that incorporates RF, Microwave, Analog and Mixed Signal and Optical semiconductor technologies. MACOM has achieved certification to the IATF16949 automotive standard, the AS9100D aerospace standard, the ISO9001 international quality standard and the ISO14001 environmental management standard. MACOM operates facilities across the United States, Europe, Asia and is headquartered in Lowell, Massachusetts. To learn more, visit www.macom.com.
Company Contact:
MACOM Technology Solutions Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 hours ago
- Miami Herald
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: CLDI: In an exclusive interview, Eric Poma, Ph.D., CEO of Calidi Biotherapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Calidi's pioneering approach to precision genetic medicine, enabled by its proprietary RedTail platform-an engineered, systemically delivered viral therapy designed to reach metastatic sites and deliver genetic medicines to treat tumors. The platform cloaks potent genetic payloads, such as IL-15 superagonist, within a human-derived envelope, allowing the virus to evade immune detection and circulate throughout the body. Preclinical data showcased at AACR and ASCO demonstrated that a single dose of Calidi's lead candidate, CLD-401, not only eliminated metastatic tumors but also primed immune memory, offering the potential to prevent recurrence. With its scalable, non-integrating viral backbone and ability to deliver multiple genetic payloads, RedTail positions Calidi to address a vast oncology market projected to exceed $560 billion by 2033. The company is advancing toward IND filing in 2026, while exploring strategic pharma partnerships to support global commercialization. Calidi's capital-efficient business model, strengthened balance sheet, and next-generation pipeline targeting both cancer and autoimmune diseases highlight its strong potential to deliver value to shareholders. Dr. Steven Quay, CEO of Atossa Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Atossa's strategic approach to redefining breast cancer treatment through its lead clinical candidate, (Z)-endoxifen - a next-generation SERM with best-in-class potential. With a focus on metastatic breast cancer, where current therapies often fall short, Atossa is advancing multiple Phase 2 studies that demonstrate strong clinical activity, improved tolerability, and a favorable safety profile. The presentation will highlight recent progress across key development programs, upcoming milestones, and how the Company's differentiated science and capital-efficient model are designed to deliver both clinical impact and long-term shareholder value. CLDI and ATOS are clients of RedChip Companies. Please read our full disclosure at About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company's proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ SOURCE: RedChip Companies, Inc.
Business Wire
4 hours ago
- Business Wire
BioConsortia Closes Financing to Accelerate Launch of Next-Generation Nitrogen-Fixing Biofertilizer and Fuel Global Expansion
BUSINESS WIRE)--BioConsortia, Inc., a leader in microbial innovation for sustainable agriculture, announced today it has secured $15 million in funding from its long-standing internal investors, led by Otter Capital and affiliated funds. 'This investment, one in a series of recurring financings from our internal investors, reflects their deep confidence in BioConsortia's science, strategy, and commercial momentum,' said Marcus Meadows-Smith, BioConsortia's CEO. 'Their investments total $95 million and bring BioConsortia to this exciting moment in the company's history.' The new funding will accelerate the global launch of Always-N™, BioConsortia's groundbreaking nitrogen-fixing seed treatment for industrial corn and support continued expansion of its discovery and development engine at the company's Davis, California headquarters. Always-N enables farmers to maintain crop yields while reducing reliance on synthetic nitrogen fertilizers—significantly lowering greenhouse gas emissions and improving soil health. Applied as a seed treatment, Always-N delivers consistent field performance and is the only nitrogen-fixing biofertilizer combining advanced gene editing and extended viability exceeding two years. "Synthetic nitrogen fertilizers are essential to modern agriculture, but their overuse comes at a steep environmental cost,' said Meadows-Smith. 'With Always-N, we offer a powerful, sustainable alternative—backed by cutting-edge science and built for real-world performance.' Roughly half of applied synthetic nitrogen is never absorbed by crops. Instead, it runs off into waterways or is broken down in soil, releasing nitrous oxide—a greenhouse gas 300 times more potent than CO₂. As regulatory and market pressure builds for climate-smart farming, demand for sustainable alternatives like Always-N is growing rapidly. Following its successful commercial debut in New Zealand in 2024, Always-N is now preparing for broader market entry, supported by key global partners including The Mosaic Company in row crops in the Americas. The new funding enables BioConsortia to scale manufacturing, build inventory, and expand market access in anticipation of the upcoming growing season. Always-N is powered by BioConsortia's discovery and development platform - an integrated engine using proprietary tools for microbial discovery, selection, and optimization. It begins with Advanced Microbial Selection™ (AMS) to identify high-performing plant-associated microbes, then uses GenExpress™ and GenePro™ tools to enhance traits such as nitrogen fixation, disease and pest control, and shelf-life. In addition to Always-N™, BioConsortia is advancing a robust pipeline of next-generation biostimulants, fungicides, nematicides, and insecticides—engineered for extended shelf life, ease of use, and superior field efficacy. Since its founding in 2014, BioConsortia has validated its platform across diverse crops, geographies, and soil types. Field trials have consistently demonstrated the efficacy of its microbial biofertilizers, fungicides, nematicides, and insecticides—delivering growers new tools for sustainable, high-yield farming. About BioConsortia At BioConsortia, we are pioneering the next generation of agricultural biologicals through cutting-edge microbial gene editing. Our breakthroughs in editing only the most stable microbes unlock unprecedented performance in nitrogen fixation, biocontrol, and biostimulants—delivering solutions that are more effective, more consistent, and easier to use than anything on the market today. By precisely enhancing natural microbial traits, we're creating products that outperform both traditional chemicals and first-generation biologicals—with longer shelf life, extended life on seed, robust field efficacy, and compatibility with existing farm systems. Our AMS platform supports rapid discovery and development of superior wild type microbial products, and our gene-edited innovations redefine what's possible in sustainable agriculture. Since its founding in 2014, BioConsortia has built a reputation for delivering science-driven, field-proven solutions across a wide range of crops, geographies, and growing conditions. Today, the company stands at the forefront of the agricultural biologicals revolution—offering farmers the tools to grow more with less, and do so sustainably.
Yahoo
6 hours ago
- Yahoo
Smart Communications Announces Strategic Investment from Cinven for Long-Term Growth
International PE firm backs Smart's bold vision to transform customer conversations in regulated industries LONDON, August 01, 2025--(BUSINESS WIRE)--Smart Communications, a leading technology company focused on helping highly-regulated organizations engage in more meaningful customer conversations, today announced that international private equity firm Cinven has acquired a majority stake in the company. This strategic investment reinforces Smart's position as the world's leading cloud-native provider of customer communications and interactive experience management technology. As part of the agreement, private equity firm Accel-KKR, which first backed Smart Communications in 2016, will retain a minority equity ownership position in the company going forward. Smart Communications' Conversation Cloud™ platform is purpose-built for regulated enterprises – empowering them to deliver personalized, compliant conversations across every channel. More than 650 leading organizations worldwide, including Zurich Insurance, Priority Health, The Pacific Financial Group, and The Bancorp, rely on Smart Communications to simplify and automate complex processes, reduce risk, improve operational efficiency, and drive secure, frictionless digital-first experiences. "Cinven's conviction in our vision and recognition of our platform, market opportunity and customer momentum reinforce the strength of what we've built," said Leigh Segall, Chief Executive Officer, Smart Communications. "With their deep expertise in technology and global growth, we are poised to accelerate our global expansion, advance our product innovation, and unlock even more value for clients in regulated industries. I'm thrilled to welcome Cinven as our new strategic partner as we mark an exciting new chapter for Smart Communications." Today's announcement follows a series of strategic investments by Smart Communications in the rapidly evolving customer conversation market. In April, Smart Communications announced the acquisition of cloud archiving provider Joisto and integrated the company's groundbreaking technology in its new SmartHUB™ digital archiving solution, which was unveiled in June. Smart's technological leadership and product innovation have also been consistently recognized by renowned analysts such as IDC, Aspire and Aragon Research. "Smart Communications' differentiated, cloud-native SaaS technology and strong track record of serving enterprise customers in regulated sectors such as financial services, insurance, and healthcare make it a true stand-out in the industry," said Thomas Railhac, partner and Head of Cinven's TMT sector team. "The company's relentless focus on innovation, deep customer relationships, and impressive growth perfectly align perfectly with Cinven's strategic vision. We're excited to partner with the team and leverage our global footprint and operational expertise to help scale the business and unlock new growth opportunities." "Smart Communications exemplifies the qualities we seek in a transformative technology investment – a truly global addressable market, an innovative product suite and outstanding customer feedback," added Adam Prindis, partner, Cinven. "The company's ability to drive tangible value for customers, while maintaining impressive operational resilience, translates into best-in-class financial metrics. We are excited to collaborate, accelerating their expansion into new geographies and verticals, and building on a truly strong foundation." Financial terms of the transaction were not disclosed. The transaction is subject to regulatory approvals and other customary closing conditions. About Smart Communications Smart Communications is the trusted choice for regulated enterprises looking to modernize complex processes and connect with customers in the moments that matter most. Its Conversation Cloud™ platform powers frictionless, compliant, digital-first experiences through omnichannel communications, intelligent data capture, and secure digital archival. More than 650 enterprises worldwide - including Zurich Insurance, Priority Health, The Pacific Financial Group, and The Bancorp - rely on Smart Communications to reduce compliance risk, boost operational efficiency, lower costs, and fast-track digital transformation that fuels business growth and elevates the customer experience. With more than 30 pre-built connectors, Smart Communications' cloud-native platform integrates effortlessly with the world's most trusted enterprise systems including Salesforce, Guidewire, DuckCreek, OneSpan, and Pega, enabling more than 60 billion mission-critical customer conversations globally, and driving faster time to value. About Cinven Cinven is a leading international private equity firm focused on building world-class global and European companies. Its funds invest in six key sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials and Technology, Media and Telecommunications (TMT). Cinven has offices in London, New York, Frankfurt, Paris, Milan, Madrid, Guernsey and Luxembourg. Cinven takes a responsible approach towards its portfolio companies, their employees, suppliers, local communities, the environment and society. Cinven Limited is authorised and regulated by the Financial Conduct Authority. Cinven Fund Management S.à r.l. is authorised and regulated by the Commission de Surveillance du Secteur Financier. In this press release 'Cinven' means, depending on the context, any of or collectively, Cinven Holdings Guernsey Limited, Cinven Partnership LLP, and their respective Associates (as defined in the Companies Act 2006) and/or funds managed or advised by any of the foregoing. For additional information on Cinven please visit and View source version on Contacts Media Contacts Red Lorry Yellow Lorry (on behalf of Smart Communications)Alex JafarzadehTel. +1 (617) 608-8852Email. smartcommunications@ Cinven Clare BradshawTel. +44 (0)7881 918 967Email. Alison RaymondTel. +44 (0)7826 856198Email. Brunswick Group (Advisers to Cinven) Cinven@ Joanna DonneTel. +44 (0)7834 307 881Email. jdonne@ Max McGahanTel. +44 (0) 7834 502369Email. mmcgahan@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
